Indegene is Established in 1998 a leading provider of digital-centric commercialization services tailored for the life sciences sector. Focused on supporting biopharmaceutical, emerging biotech, and medical devices firms, Indegene offers comprehensive assistance across various stages including drug development, clinical trials, pharmacovigilance, regulatory submissions, complaints management, and sales/marketing endeavors. Their innovative solutions empower clients to navigate product life cycles with enhanced efficiency and effectiveness. Indegene’s portfolio includes Enterprise Commercial Solutions and Omnichannel Activation solutions designed to meet the diverse commercial requirements of life sciences enterprises. Additionally, they provide Enterprise Medical Solutions and Enterprise Clinical Solutions, catering to the medical and R&D needs of their clientele.
As of December 31, 2023, the company boasted an impressive portfolio of 65 active clients. With operational hubs strategically located across North America, Europe, and Asia, Indegene has cultivated strong client relationships, counting among its clientele each of the top 20 biopharmaceutical companies worldwide by revenue for the Financial Year 2023 (Source: Everest Report).
Indegene IPO Date, Price, GMP, Review, Analysis & Details
| ipo Date | 6 May – 8 May |
| Min. Investment | ₹14,916 |
| Lot Size | 33 |
| Price Range | ₹430 – ₹452 |
| Issue Size | 1841.76 Cr |
| IPO Doc | View |
Indegene IPO Apply details
For the Indegene IPO, eligible investors have the option to apply through 3 categories:
1. Regular: In the Regular category, investors can apply within the price band of ₹430 to ₹452, with the maximum application amount set at ₹2 lakh.
2. Employee: In the Employee category, Employees can apply within the price band of ₹400 to ₹422, with the maximum application amount set at ₹2 lakh.
3. High Networth Individuals (HNIs): HNIs apply within the same price band of ₹430 to ₹452 but have the flexibility to apply for amounts ranging from ₹2 lakh to ₹5 lakh.
Indegene IPO Allotment & Listing Dates
| Indegene IPO | Date |
|---|---|
| IPO Offer Start | 6 May 2024 |
| IPO Offer Ends | 8 May 2024 |
| Allotment Finalisation | 9 May 2024 |
| Refund Initialisation | 10 May 2024 |
| Share Transfer to Demat | 10 May 2024 |
| Date of Listing | 13 May 2024 |
| Anchor Investors Lock-In End Date (50% of the investment) | June 09, 2024 |
| Anchor Investors Lock-In End Date (Remaining investment) | August 09, 2024 |
Indegene Company Financial Revenue & Profit Report
| Year | Revenue | Total Assets | Profit (PAT) |
|---|---|---|---|
| 2021 | ₹511 | 374 | 132 |
| 2022 | ₹837 | 850 | 133 |
| 2023 | ₹1,006 | 1,038 | 130 |
Indegene ipo Advantages & Disadvantages
Advantages:
Disadvantages:
Indegene IPO Shareholders List & OFFER FOR SALE
| Name of Selling Shareholders | Type | No. of Equity Shares Offered |
|---|---|---|
| Manish Gupta | Individual Selling Shareholder | Up to 1,118,596 Equity Shares |
| Dr. Rajesh Bhaskaran Nair | Individual Selling Shareholder | Up to 3,233,818 Equity Shares |
| Anita Nair | Individual Selling Shareholder | Up to 1,151,454 Equity Shares |
| Vida Trustees Private Limited (Trustee of Fig Tree Trust) in its capacity as partner of Group Life Spring | Individual Selling Shareholder | Up to 3,600,000 Equity Shares |
| BPC Genesis Fund I SPV, Ltd. | Individual Selling Shareholder | Up to 2,657,687 Equity Shares |
| BPC Genesis Fund I-A SPV, Ltd. | Individual Selling Shareholder | Up to 1,378,527 Equity Shares |
| CA Dawn Investments | Individual Selling Shareholder | Up to 10,792,650 Equity Shares |
REGISTERED AND CORPORATE OFFICE
Aspen Block G4, 3 rd Floor, Manyata Embassy
Business Park, Outer Ring Road, Nagawara,
Bengaluru 560045, Karnataka, India
E-MAIL & TELEPHONE Details
Tel: +91 80 4674 4567/ +91 80 4644 7777
Email: compliance.officer@indegene.com
www.indegene.com
